

Sterne Kessler  
Goldstein Fox



Commissioner for Patents  
U.S. Patent and  
Trademark Office  
Washington, D.C. 20231  
Telephone: (202) 371-2600  
Telex: 202 467-4256  
Fax: (202) 371-2540  
E-mail: [USPTO-PTAB@USPTO.GOV](mailto:USPTO-PTAB@USPTO.GOV)

Commissioner for Patents  
U.S. Patent and  
Trademark Office  
Washington, D.C. 20231  
Telephone: (202) 371-2600  
Telex: 202 467-4256  
Fax: (202) 371-2540  
E-mail: [USPTO-PTAB@USPTO.GOV](mailto:USPTO-PTAB@USPTO.GOV)

Receipt

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

April 9, 2002

WRITER'S DIRECT NUMBER:  
(202) 371-2625  
INTERNET ADDRESS:  
[ESTEPE@SKGF.COM](mailto:ESTEPE@SKGF.COM)

Commissioner for Patents  
Washington, D.C. 20231

*Attn: Office of Initial Patent Examination's  
Customer Service Center*

Re: U.S. Utility Patent Application  
Appl. No. 10/052,641; Filing Date: January 23, 2002  
For: **Method for Diagnosis and Therapy of Hodgkin's Lymphomas**  
Inventors: HEIDER *et al.*  
Our Ref: 0652.1910001/EKS/PSC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Corrected Official Filing Receipt;
2. A photocopy of the instant Official Filing Receipt with corrections noted in red; and
3. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

4/10/02

Commissioner for Patents  
April 9, 2002  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KISSLER, GOLDSTEIN & FOX P.L.L.C.



Eric K. Stetthe  
Attorney for Applicants  
Registration No. 36,688

EKS/PSC/lam  
Enclosures

P: USRS PChor 0652 191 pto ofrrequestforcorrectionpto:tm

RECEIVED

APR 15 2002

TECH CENTER 1600/29



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Heider *et al.*

Appl. No. 10/052,641

Filed: January 23, 2002

For: **Method for Diagnosis and  
Therapy of Hodgkin's  
Lymphomas**

Confirmation No. 3959

Art Unit: 1642

Examiner: *To be assigned*

Atty. Docket: 0652.1910001/EKS/PSC

**Request for Corrected Official Filing Receipt**

Commissioner for Patents  
Washington, D.C. 20231

Attn: Office of Initial Patent  
Examination's Customer  
Service Center

Sir:

Applicants hereby request that a corrected Official Filing Receipt be issued and sent to the undersigned representative. Specifically, the following corrections to the Official Filing Receipt are requested:

In Applicant(s) section, line 1, please delete "Australia" and insert --Austria--;

line 2, please delete "Australia" and insert --Austria--; and

line 3, please delete "Australia" and insert --Austria--.

In support of the above request, a photocopy of the instant Official Filing Receipt is enclosed with the corrections noted in red. It is requested that a corrected Official Filing Receipt be issued, and sent to the undersigned at the earliest possible time.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe  
Attorney for Applicants  
Registration No. 36,688

4/10/02

Date: 4/9/02  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10052,641	01/23/2002	1642	740	0652.1910001	3	6	1

O 1 APR 10 2002

2611  
 STEENE, KESSLER, GOLDSTEIN & FOX PLLC  
 1100 NEW YORK AVENUE, N.W., SUITE 600  
 WASHINGTON, DC 20005-3934

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

CONFIRMATION NO. 3959

FILING RECEIPT



\*OC000000007726174\*

Date Mailed: 03/27/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Karl-Heinz Heider, Stockerau, AUSTRALIA;  
 Kurt Zatloukal, Graz, AUSTRALIA;  
 Christine Beham-Schmid, Graz, AUSTRALIA;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/331,254 12/21/1999  
 WHICH IS A 371 OF PCT/EP97/07081 12/17/1997

APR - 1 2002

## Foreign Applications

GERMANY 196 53 607.3 12/20/1996

MA  
 CUS  
 PSC  
 APR (4/13) 1/2  
 4/3/02  
 b  
 PC

If Required, Foreign Filing License Granted 03/27/2002

Projected Publication Date: 07/04/2002

Non-Publication Request: No

Early Publication Request: No

## Title

Method for diagnosis and therapy of Hodgkin's lymphomas

## Preliminary Class

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).